biostudies-literatureKoehm MFraunhofer Cluster of Excellence for Immune-Mediated DiseasesFrauenhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, GermanyJanssen CilagLOEWE Zentrum Translational Medicine and Pharmacologye003538https://www.ebi.ac.uk/biostudies/studies/S-EPMC10749014biostudies-literatureUnknown9(4)<h4>Background</h4>The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.<h4>Objective</h4>To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with placebo or methotrexate (MTX).<h4>Methods</h4>We evaluated baseline characteristics, key treatment outcomes and adverse events stratified by sex, with a focus on outcomes that did not include erythrocyte sedimentation rate (ESR) as a component due to the known elevation of ESR in females.<h4>Results</h4>A total of 166 patients were treated with ustekinumab+MTX (3RMD openDifferences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.PMC10749014Not applicableBrandt JDemary WKellner HBurmester GRBraun JBrandt-Jurgens JRech JSchwenke HBehrens FKoehm MThiele AFinzel SRubbert-Roth AWassenberg SFoldenauer ACBenesova KMax RThaci DKofler DKiltz USieburg MAlten RHWalter JKofler DMKastner PRossmanith TKruger KLorenz GMUST Investigator Groupvon Hinuber UBergner RKleye APoddubnyy DVoll REfalseDifferences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial.<h4>Background</h4>The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored.<h4>Objective</h4>To conduct exploratory post hoc analyses of sex-stratified data from the MUST trial, an investigator-initiated, multicentre, phase 3b study in which patients with active PsA initiating treatment with open-label ustekinumab were randomised to treatment with placebo or methotrexate (MTX).<h4>Methods</h4>We evaluated baseline characteristics, key treatment outcomes and adverse events stratified by sex, with a focus on outcomes that did not include erythrocyte sedimentation rate (ESR) as a component due to the known elevation of ESR in females.<h4>Results</h4>A total of 166 patients were treated with ustekinumab+MTX (32023-01-01T00:00:00Z2023 Dec2026-07-15T01:18:04.508Z2025-06-01T01:18:17.248ZS-EPMC107490143811419810.1136/rmdopen-2023-003538